panel discussion: advances in lung cancer treatment | crsf 2023 review
Published 4 months ago • 35 plays • Length 20:30Download video MP4
Download video MP3
Similar videos
-
9:02
expert panel discussion on advances in lung cancer treatment | crsf 2023 year end review
-
20:53
expert panel discussion: advancements in lung cancer treatment | crsf 2023 year end review
-
23:17
expert panel discussion: latest insights in lung cancer treatment | crsf 2023 review
-
29:44
panel discussion: combination therapy in advanced egfrm nsclc | crsf 2023 review
-
35:05
cutting-edge advances in lung cancer treatment: crsf 7th annual year end
-
9:21
panel discussion: advancements in nsclc treatment | crsf
-
23:31
07th masterclass: panel discussion on maximizing osimertinib outcomes in egfrm lung cancer | dr. pai
-
27:09
expert panel discussion: greometry trial & crsf lung cancer review
-
40:32
optimal sequencing of alk inhibitiors in the management of alk positive mnsclc | crsf
-
19:01
dr darshit shah debate dr gunjesh kumar singh immunotherapy sequencing in early stage resectable lun
-
12:40
regeneration & repair of the heart & lung, michael bollong, phd
-
35:48
crsf 7th masterclass | dr. akhil kapoor moderates panel on locally advanced lung cancer (case 1)
-
21:03
panel discussion: insights from abstracts | crsf 2023 review
-
29:37
dr minit shah issues in the management of geriatric cases advanced stage lung cancer | crsf
-
35:08
unleashing hope: redefining survival outcomes with dual icis | crsf 2023 review
-
11:22
ers vision - a new prognosis for lung cancer: major advances in diagnostics and therapeutics
-
33:54
2021 west oncology | lung cancer | panel discussion and q&a
-
20:45
dr bivas biswas | turning the tides for stage iii nsclc towards the curative intent
-
31:26
breaking boundaries: 5-year survival in es sclc | crsf 7th annual lung cancer review
-
10:26
advances in lung cancer treatments
-
36:10
case based panel discussion | dr. praveen jain | managing early stage lung cancer patients
-
1:01:28
panel discussion | dr randeep singh | durvalumab in stage iii nsclc